Myriad Genetics (STU:MYD) Notes Receivable: €0.0 Mil (As of Mar. 2026)


STU:MYD Myriad Genetics Inc STU:MYD
49 GF Score
Price €5.30
GF Value €13.05
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Notes Receivable?

Myriad Genetics STU:MYD +2.91% 49 Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 49/100 and a GF Value™ of €13.05 (Possible Value Trap). The stock has 5 warning signs investors should review.

Myriad Genetics's Notes Receivable for the quarter that ended in Mar. 2026 was €0.0 Mil.

Myriad Genetics Notes Receivable Related Terms

Myriad Genetics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Notes Receivable Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Myriad Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:MYD
49GF Score
Myriad Genetics Inc STU:MYD
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
Myriad Genetics (STU:MYD) has a Notes Receivable of €0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Notes Receivable too high?
Myriad Genetics' current Notes Receivable is €0.0 Mil. Overall, Myriad Genetics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Notes Receivable compare to FLGT and CSTL?
Myriad Genetics' Notes Receivable of €0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.05, compared to a current price of €5.30 — trading 59.4% below its estimated fair value. The current Notes Receivable is €0.0 Mil. Myriad Genetics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.30 is trading 59.4% below its estimated GF Value™ of €13.05. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Notes Receivable: €0.0 Mil
  • GF Value™: €13.05 vs. price of €5.30 (59.4% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
49GF Score

Get the complete analysis for STU:MYD

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.30
Price
€13.05
GF Value